Zhang Lab is devoted to using the cutting-edge genomics and bioinformatics technologies to study critical issues of cancer biology, including revealing the genetic and immune factors underlying tumorigenesis, tumor microenvironment and drug resistance. The current main research directions include: 1) applying single cell sequencing technology to dissect tumor microenvironment, especially the accurate composition and functional status of tumor-infiltrating immune cells; 2) dissecting the heterogeneity of tumor and the impact on cancer biology and drug resistance; 3) developing innovative bioinformatics tools and resources to analyze, integrate, and visualize single-cell genomic data and large-scale cancer genomic data to reveal novel targets as well as the genomic mechanisms underlying tumor heterogeneity and immune response differences.

Zemin Zhang received his bachelor degree in Biology Department of Nankai University in 1988 and went to USA by CUSBEA. He obtained his PhD in Biochemistry and Molecular Biology Department of Penn State University in 1995. After the postdoc training in University of California, San Francisco from 1995 to 1998, he worked in GENENTECH, USA, where he served as postdoctoral supervisor, department director, and the principal scientist of bioinformatics. His previous achievements include the first whole-genome sequencing study of solid tumor, the first systematic assessment of viral insertion on liver cancer, and the first computational method to discriminate cancer driver mutations from passenger mutations. His studies led to the discovery of multiple cancer-specific drug targets and 60 US patents granted. In 2014, he joined Peking University. He was awarded the Bollinger Ingelheim Fellow Award in 2017 and the Bayer Investigator Award in 2019, and his research achievements have been selected in the Top Ten Biological Science Advances of China in 2017, the Top Ten Biomedical Advances of China in 2017, the Cell Press Paper of the Year Award in China for 2017 and 2019, the Top Ten Bioinformatics Progresses of China in 2018 and 2019, the Cell Press 2020 Best of Cell.

张泽民实验室致力于用前沿的基因组学和生物信息学技术来解决癌症生物学中的重要问题，利用计算和实验相结合方法来揭示肿瘤发生过程、肿瘤微环境和对药物响应中的系统变化和重要遗传因素，以推进癌症免疫治疗和靶向治疗的发展。主要的研究方向包括：一，应用单细胞测序技术来研究肿瘤微环境特别是肿瘤浸润免疫细胞的精确组成、相互作用、以及功能状态；二，研究肿瘤的异质性、基因组机制、及其对耐药性的影响；三，开发原创的生物信息学工具和数据库，来进行单细胞基因组数据和癌症基因组大数据的整合、分析和可视化，以揭示癌症的亚型、驱动基因以及其他致癌因素的遗传基础，从而发现新型癌症靶点和标记物。

张泽民教授，1988 年本科毕业于南开大学生物系, 1989 年由 CUSBEA 项目赴美留学。1995 年研究生毕业于宾州州立大学生物化学和分子生物学专业, 获得博士学位 ;1995-1998年在美国旧金山加州大学进行博士后研究工作。1998年起任职于美国 GENENTECH 公司开始生物信息学研究, 曾任博士后导师, 生物信息学部主任, 生物信息首席科学家。前期主要工作包括: 在世界上首次报道实体癌的全基因组测序; 首次在全基因组水平研究病毒插入事件在肝癌发生发展中的作用; 首次通过计算方法鉴别癌症的驱动突变。通过对癌症高通量数据的分析, 成功地发现了多种特异性抗癌靶点, 获得60多项美国专利授权。2014 年加入北京大学。2017年获The Boehringer Ingelheim Investigator Award，2017年获Bayer Investigator Award, 相关成果入选2017年度中国十大医学科技新闻、2017年度中国生命科学十大进展、细胞出版社2017和2019中国年度论文、2018和2019年度中国生物信息十大进展、2020年细胞杂志最佳论文。